Effects of the angiotensin II type 1 receptor antagonist telmisartan on monocyte adhesion and activation in patients with essential hypertension

Hypertension Research

Volumn 30, Issue 6, 2007, Pages 521-528

  Syrbe, Uta ^a   Moebes, Anja ^a   Scholze, Jürgen ^a   Swidsinski, Alexander ^b   Dörfel, Yvonne ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Adhesion; Chemokine; Hypertension; Monocyte; Telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CD11B ANTIGEN; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; TELMISARTAN;

ADULT; AGED; ARTICLE; CELL ACTIVATION; CELL ADHESION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MONOCYTE; MONOTHERAPY; PROTEIN EXPRESSION;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIGENS, CD11A; ANTIGENS, CD11B; ANTIGENS, CD80; ANTIGENS, CD86; BENZIMIDAZOLES; BENZOATES; CASE-CONTROL STUDIES; CELL ADHESION; FEMALE; HUMANS; HYPERTENSION; INTERCELLULAR ADHESION MOLECULE-1; MALE; MIDDLE AGED; MONOCYTES; RECEPTORS, CHEMOKINE;

EID: 34447546543     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.30.521     Document Type: Article

References (45)

1. Simon A, Levenson J: Stratification of vascular risk in hypertension and therapeutic perspective. Am J Hypertens 1995; 8: 45-48.
2. Tummala PE, Chen X-L, Sundell CL, et al: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999; 100: 1223-1229.
3. Schulman IH, Zhou MS, Raij L: Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension. J Hypertens Suppl 2006; 24: S45-S50.
4. Ross R: Atherosclerosis - an inflammatory diseases. N Engl J Med 1999; 340: 115-126.
5. Hartwell DW, Wagner DD: New discoveries with mice mutant in endothelial and platelet selectins. Thromb Haemost 1999; 82: 850-857.
6. Tedder TF, Steeber DA, Chen A, Engel P: The selectins: vascular adhesion molecules. FASEB J 1995; 9: 866-873.
7. Imhof BA, Aurrand-Lions M: Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 2004; 4: 432-444.
8. Butcher EC: Leukocyte-endothelial cell recognition: three (or more) steps to specifity. Cell 1991; 67: 1033-1036.
9. Alexander RW: Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response; a new perspective. Hypertension 1995; 25: 155-161.
10. McCarron RM, Wang L, Siren AL, Spatz M, Hallenbeck JM: Monocyte adhesion to cerebromicrovascular endothelial cells derived from hypertensive and normotensive rats. Am J Physiol 1994; 267: H2491-H2497.
11. Libby P: What have we learned about the biology of atherosclerosis? The role of inflammation. Am J Cardiol 2001; 88: 3J-6J.
12. Dörffel Y, Lätsch C, Stuhlmüller B, et al: Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 1999; 34: 113-117.
13. Tanaka C, Mannami T, Kamide K, et al: Single nucleotide polymorphisms in the interleukin-6 gene associated with blood pressure and atherosclerosis in a Japanese general population. Hypertens Res 2005; 28: 35-41.
14. Dörffel Y, Franz S, Pruß A, et al: Preactivated monocytes from hypertensive patients as a factor for atherosclerosis? Atherosclerosis 2001; 157: 151-160.
15. Kranzhofer R, Browatzki M, Schmidt J, Kubler W: Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 1999; 257: 826-828.
16. Szabo C, Pacher P, Zsengeller Z, et al: Angiotensin II-mediated endothelial dysfunction: role of poly(ADP-ribose) polymerase activation. Mol Med 2004; 10: 28-35.
17. Vazquez-Oliva G, Fernandez-Real JM, Zamora A, Vilaseca M, Badimon L: Lowering of blood pressure leads to decreased circulating interleukin-6 in hypertensive patients. J Hum Hypertens 2005; 19: 457-462.
18. Sanada H, Midorikawa S, Yatabe J, et al: Elevation of serum soluble E- and P-selectin in patients with hypertension is reversed by benidipine, a long-acting calcium channel blocker. Hypertens Res 2005; 28: 871-878.
19. Mervaala EM, Muller DN, Park JK, et al: Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension 1999; 33: 389-395.
20. Brasier AR, Recinos A, Eledrisi MS: Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22: 1257-1266.
21. Dandona P, Kumar V, Aljada A, et al: Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leucocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an anti-inflammatory action. J Clin Endocrinol Metab 2003; 88: 4496-4501.
22. Uchida H, Nakamura Y, Kaihara M, et al: Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Hypertens Res 2004; 27: 545-550.
23. Sasaki DT, Dumas SE, Engleman EG: Discrimination of viable and non-viable cells using propidium iodide in two color immunofluorescence. Cytometry 1987; 8: 413-420.
24. Dörffel Y, Bresan V, Stuhlmüller B, Dörffel WV, Pruss A, Scholze J: Candesartan - an inhibitor of monocyte activation in hypertensive patients? Perfusion 2002; 15: 96-101.
25. Hahn AWA, Jonas F, Bühler FR, Resink TJ: Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994; 347: 178-180.
26. Wingren AG, Parra E, Varga M, et al: T cell activation pathways: B7, LFA-3, and ICAM-1 shape unique T cell profiles. Crit Rev Immunol 1995; 15: 235-253.
27. Heinzelmann M, Mercer-Jones MA, Gardner SA, Wilson MA, Polk HC: Bacterial cell wall products increase monocyte HLA-DR and ICAM-1 without affecting lymphocyte CD18 expression. Cell Immunol 1997; 176: 127-134.
28. Hmama Z, Knutson KL, Herrera-Velit P, Nandan D, Reiner NE: Monocyte adherence induced by lipopolysaccharide involves CD14, LFA-1, and cytohesin-1. J Biol Chem 1999; 274: 1050-1057.
29. Issekutz TB: In vivo blood monocyte migration to acute inflammatory reactions, IL1α, TNF-α, IFN-γ, and C5a utilizes LFA-1, Mac-1, and VLA-4. J Immunol 1995; 154: 6533-6540.
30. Greenfield EA, Nguyen KA, Kuchroo VK: CD28/B7 costimulation: a review. Crit Rev Immunol 1998; 18: 389-418.
31. Luster AD: Chemokines - chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436-445.
32. Ishibashi M, Hiasa K, Zhao Q, et al: Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodelling. Circ Res 2004; 94: 1203-1210.
33. Zernecke A, Liehn EA, Gao J-L, Kuziel WA, Murphy PM, Weber C: Deficiency in CCR5 but not CCR1 protects against neointima formation in atherosclerosis-prone mice: involvement of IL-10. Blood 2006; 107: 4240-4243.
34. 1 receptor autoantibodies and monocyte stimulation in hypertensive patients. Am J Hypertens 2003; 16: 827-833.
35. DeSouza CA, Dengel DR, Macko RF, Cox K, Seals DR: Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997; 10: 1335-1341.
36. Madej A, Okopien B, Kowlski J, Haberka M, Herman ZS: Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension. Pharmacol Rep 2005; 57: 878-881.
37. Roep BO, Heidenthal E, de Vries RRP: Soluble forms of intercellular adhesion molecule-1 in insulin dependent diabetes mellitus. Lancet 1994; 343: 1540-1543.
38. Hackmann A, Abe Y: Levels of soluble cell adhesion molecules in patients with dyslipidemia. Circulation 1996; 93: 1334-1338.
39. Fliser D, Buchholz K, Haller H, European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators: Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107.
40. Prasad A, Koh KK, Schenke WH, et al: Role of angiotensin II type 1 receptor in the regulation of cellular adhesion molecules in atherosclerosis. Am Heart J 2001; 142: 248-253.
41. Kintscher U, Wakino S, Kim S, Fleck E, Hsueh WA, Law RE: Angiotensin II induces migration and Pyk2/paxillin phosphorylation of human monocytes. Hypertension 2001; 37: 587-593.
42. Thomas TH, Advani A: Inflammation in cardiovascular disease and regulation of the actin cytoskeleton in inflammatory cells: the actin cytoskeleton as a target. Cardiovasc Hematol Agents Med Chem 2006; 4: 165-182.
43. Bayer AL, Heidkamp MC, Patel N, Porter MJ, Engman SJ, Sarnarel AM: Pyk2 expression and phosphorylation increases in pressure overload-induced left ventricular hypertrophy. Am J Physiol Heart Circ Physiol 2002; 283: H695-H706.
44. Rocic P, Griffin TM, McRae CN, Lucchesi PA: Altered Pyk2 phosphorylation by Ang II in hypertensive vascular smooth muscle. Am J Physiol Heart Circ Physiol 2003; 282: H457-H465.
45. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB: Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20: 645-651.